Recent Research Funding

Carla Frederick, MD, with a patient in a clinical trial.

Carla A. Frederick, MD, conducts research with patients in international clinical trials. Gilead Sciences Inc., the Cystic Fibrosis Foundation and others have provided funding.

Research by members of our division is strongly supported by extramural and intramural funding.

We are backed by competitively awarded funding from sources including:

  • National Institutes of Health
  • U.S. Department of Veterans Affairs
  • New York state 

Our fellows have received prestigious awards, including the American Academy of Sleep Medicine Physician Sleep Scientist Training Award.

Our division’s research is also supported by various pharmaceutical companies. Our pharmaceutical funding support goes toward investigator-initiated single-center studies and multi-center clinical trials. 

Additionally, our newly hired faculty members receive research support from the university.

Our funded research efforts include:

Carla Frederick, MD

  • TherapeuticS Development Center (TDC). Carla Frederick (Principal Investigator), Danielle Goetz (Co-Investigator). Cystic Fibrosis Foundation Therapeutics, Inc. $443,986. 1/1/2015-12/1/2018.
  • Success with Therapies Research Consortium. Carla Frederick (Principal Investigator). Cystic Fibrosis Foundation. $108,000. 8/1/2014-7/1/2018.

Philippe Jaoude, MD

  • ASMF PSTA. Philippe Jaoude (Principal Investigator). American Sleep Medicine Foundation. $75,000. 9/1/2014-9/1/2016.

M. Jeffery Mador, MD

  • A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25MCG with Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardio. M. Jeffery Mador (Principal Investigator). BIMR. $48,000. 2/1/2014-2/1/2017.
  • Double-blind, Randomized, Placebo-Controlled, Parallel-Group, Phase IV Study to Evaluate the Effect of Acidinium Bromide on Long-Tern Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (Ascent). M. Jeffery Mador (Principal Investigator). BIMR. $52,000. 11/1/2013-12/1/2016.

Manoj Mammen, MD

  • UB CAT: Circuit Clinical Data Collection and Analytics Systems, phase II. Manoj Mammen (Principal Investigator). UB CAT. $197,563. 7/1/2018-6/1/2019.
  • CTSI Pilot Study: Linking New York State Databases to Identify Risk Factors and Gaps in care for rural and urban health disparities in lung cancer. Manoj Mammen (Co-Investigator). CTSI. $50,000. 5/1/2018-4/1/2019.
  • UB CAT: Circuit Clinical Data Collection and Analytics Systems. Manoj Mammen (Principal Investigator). UB CAT. $486,184. 11/1/2017-10/1/2018.
  • UB Genome, Environment, and Microbiome Community of Excellence (GEM) pilot study grant:The Airway Microbiome and Lung cancer in a COPD cohort. Manoj Mammen (Principal Investigator). University at Buffalo. $20,000. 7/1/2016-6/1/2019.
  • Epigenetics profiling of Exacerbation Susceptibility in Chronic Obstructive Pulmonary Disease. Manoj Mammen (Co-Investigator). CTSA UB UR Collaborative Genomics Pilot Program Award. $75,000. 7/1/2016-7/1/2017.

Sanjay Sethi, MD